Preparation and purification of an end to end coupled mEGF-dextran conjugate.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Bioconjugate chemistry

• Publication date

  1997-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BC970173MPMID 9404668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Binding, internalization and degradation of EGF‐dextran conjugates in two human bladder‐cancer cell lines

  1997cited by this paper
• Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy.

  1996cited by this paper
• Epidermal‐growth‐factor‐receptor expression is associated with rapid tumor proliferation in bladder cancer

  1994cited by this paper
• Dose-dependent plasma clearance of human epidermal growth factor in rats.

  1994cited by this paper
• Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor.

  1994cited by this paper
• Internalization and excretion of epidermal growth factor‐dextran‐associated radioactivity in cultured human squamous‐carcinoma cells

  1994cited by this paper
• Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy.

  1993cited by this paper
• Binding, Internalization and Excretion of TGFα-dextran Associated Radioactivity in Cultured Human Glioma Cells

  1993cited by this paper
• Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study.

  1992cited by this paper
• Epidermal growth factor and its receptor: Markers of— and targets for—chemoprevention of bladder cancer

  1992cited by this paper
• Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells

  1992cited by this paper
• Binding of epidermal growth factor‐dextran conjugates to cultured glioma cells

  1991cited by this paper
• Effects of a highly concentrated hypertonic saline-dextran volume expander on cardiopulmonary function in anesthetized normovolemic horses.

  1991cited by this paper
• Effect of glycosylation of bacterial amylase on stability and active site conformation.

  1991cited by this paper
• Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules.

  1990cited by this paper
• Functional protein-polysaccharide conjugate prepared by controlled dry-heating of ovalbumin-dextran mixtures.

  1990cited by this paper
• Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling.

  1989cited by this paper
• Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the egf receptor

  1989cited by this paper
• Gene Amplification in Malignant Human Gliomas: Clinical and Histopathologic Aspects

  1988cited by this paper
• Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines

  1988cited by this paper
• Epidermal growth factor (urogastrone)-stimulated gluconeogenesis in isolated mouse hepatocytes.

  1987cited by this paper
• Evidence for progressional changes in the human malignant glioma line U-343 MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor.

  1987cited by this paper
• Covalent linkage of carboxypeptidase G2 to soluble dextrans--I. Properties of conjugates and effects on plasma persistence in mice.

  1987cited by this paper
• Receptors for epidermal growth factor and other polypeptide mitogens.

  1987cited by this paper
• Clinical Pharmacokinetic Considerations in the Use of Plasma Expanders

  1987cited by this paper
• Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway

  1986cited by this paper
• Distribution of epidermal growth factor binding sites in the adult rat liver.

  1986cited by this paper
• MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF.

  1985cited by this paper
• Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

  1985cited by this paper
• Expression of epidermal growth factor receptors in human brain tumors.

  1984cited by this paper
• Enhanced stability of beta-galactosidase in parenchymal and nonparenchymal liver cells by conjugation with dextran.

  1983cited by this paper
• Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells

  1982cited by this paper
• Purification and properties of glucosyltransferase responsible for water-insoluble glucan synthesis from Streptococcus mutans

  1982cited by this paper
• Epidermal growth factor.

  1979cited by this paper
• Studies on the kinetics and renal excretion of low and high molecular weight dextrans in preterm babies, newborns and young infants

  1977cited by this paper
• 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts

  1976cited by this paper

• Selection of DNA‐Encoded Dynamic Chemical Libraries for Direct Inhibitor Discovery

  2020cites this paper
• Selection of DNA-encoded Dynamic Chemical Libraries for Direct Inhibitor Discovery.

  2020cites this paper
• Glucose/galactose/dextran-functionalized quantum dots, iron oxide and doped semiconductor nanoparticles with <100 nm hydrodynamic diameter

  2012cites this paper
• Axon Tracing with Functionalized Paramagnetic Nanoparticles

  2011cites this paper
• Aspects of Tumour Targeting : Preclinical Studies on Human Malignant Cells in vitro

  2009cites this paper
• Targeting malignant glioma cells in vitro using platelet-derived growth factor AA-based conjugates

  2009cites this paper
• Aspects of Tumour Targeting

  2009cites this paper
• Tumour targeting using radiolabelled EGF conjugates : preclinical studies.

  2004cites this paper
• Vectorial delivery of macromolecules into cells using peptide-based vehicles.

  2001cites this paper
• Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF.

  1999cites this paper
• Conjugate chemistry and cellular processing of EGF-dextran.

  1999cites this paper
• Fluorescent neoglycoproteins: antibody-aminodextran-phycobiliprotein conjugates.

  1999cites this paper
• Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.

  1998cites this paper